Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) just unveiled an update.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced proposed amendments to its Articles of Association, which include expanding its business scope to cover pharmaceutical packaging materials and products. Additionally, the company plans to abolish its Supervisory Committee, with its functions being transferred to the audit committee of the Board, aligning with the new Company Law and other regulatory requirements. These changes aim to enhance operational standards and will be subject to approval at an extraordinary Shareholders’ meeting.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the research, development, production, and sales of pharmaceutical products. The company is expanding its business scope to include pharmaceutical packaging materials and products.
Average Trading Volume: 3,974,437
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$454.4B
For an in-depth examination of 1276 stock, go to TipRanks’ Overview page.